Escalation vs. induction therapy in multiple sclerosis

Natalizumab treatment in paediatric multiple sclerosis: a case of induction, de-escalation and escalation.

Pediatric multiple sclerosis: Escalation and emerging treatments.

Over the last 20 years, there have been significant advances in multiple sclerosis (MS) therapeutics, with regulatory approval for 13 therapies in adults by the European Medicines Agency (EMA) and Food and Drug Administration. However, there is only limited approval for interferon-β and glatiramer acetate use in children 12 years and older by the EMA. Availability of disease-modifying therapies...

P 151: Clinical Trial in Cell Therapy of Multiple Sclerosis

Neuroinflammation is a disorder that causes neurological disease. Neuroinflammation has a significant role in induce of Multiple sclerosis (MS) and one of the situations that must be treated stops the ongoing process of inflammation against the CNS by self-reactive lymphocytes. According to the successful results that were obtained from the pre-clinical phase of cell therapy, many studies were ...

Group Quality of Life Therapy in Patients with Multiple Sclerosis

Objective: Multiple sclerosis (MS) has several physical, psychological, and psychiatric symptoms. Regarding the psychological impact of MS on aspects of life, this study sought to examine the effect of group quality of life therapy on depression and anxiety in these patients. Methods: Two groups of 15 matched patients with MS were randomly assigned to experimental and control groups after co...

P 52: Interferon beta-a1 vs. Teriflunomide for Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory disorder, in which neurons in central nervous system (CNS) become demyelinated .MS is named for its formation of plaques due to sclerosis of myelin. Variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. It is commonly characterized by recurrent relapses and often followed by severe neurological disabi...